Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases

Satake, Hironaga; Hashida, Hiroki; Tanioka, Hiroaki; Miyake, Yasuhiro; Yoshioka, Shinichi; Watanabe, Takanori; Kyogoku, Takahisa; Inukai, Michio; Kotake, Toshihisa; Okita, Yoshihiro; Matsumoto, Toshihiko; Yasui, Hisateru; Kotaka, Masahito; Kato, Takeshi; Kaihara, Satoshi; Tsuji, Akihito

doi:10.1002/onco.13816

Cited by 4 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit of oxaliplatin-based chemotherapy was suggested also by Sakamoto et al [ 42 ] in a small study of 24 patients treated with FOLFOX4 or modified FOLFOX6 along with a single-arm phase II study by Satake et al [ 35 ] that investigated the efficacy of CAPOX in 28 patients. The favorable role of FOLFOX and oxaliplatin plus 5-FU was proved by Kim et al [ 44 ] in a study with sixty patients that were compared with historical controls.…”

Section: Resultsmentioning

confidence: 88%

See 1 more Smart Citation

Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review

Georgilis

Gavriatopoulou

Tsilimigras

et al. 2023

JCM

View full text Add to dashboard Cite

The liver is the most common site of colorectal cancer metastatic spread. Although metastasectomy is the gold standard for fit patients with resectable colorectal cancer liver metastases (CRLMs), their management after surgical treatment remains controversial. The objective of this systematic review was to collate the currently available data of the agents used in the adjuvant setting in order to define the most optimal therapeutic strategy. A systematic review of the literature was conducted by searching PubMed/Medline and Cochrane library databases. We included studies that evaluated the efficacy, the tolerability and the safety profile of various chemotherapeutic agents that are used as adjuvant treatment after surgical resection of CRLMs. The outcomes of interest were regression-free survival (RFS), disease-free survival (DFS), overall survival (OS) and severe toxicities. From 543 initial articles, 29 publications with 7028 patients were finally included. In general, the results of the eligible studies indicated that adjuvant therapy after resection of CRLMs led to improved RFS/DFS rates, but this benefit did not contribute to a statistically significant prolongation of OS. Moreover, the choice of the therapeutic strategy, namely systematic or regional chemotherapy or the combination of both, did not seem to have a differential impact on patient outcomes. However, these results should be interpreted with caution since the majority of the chosen studies are of low or moderate quality. In this context, further high-quality clinical trials conducted on patient sub-populations with modern therapies are required in order to reduce in-study and between-study heterogeneity and determine which patients are expected to derive the maximum benefit from adjuvant therapy after surgery for CRLMs.

show abstract

Section: Resultsmentioning

confidence: 88%

“…In the study of Satake et al [ 35 ], among 28 participants, 20 (71.4%, 95% CI: 53.6–89.3%) were able to complete the protocol treatment. Capecitabine was reduced in 10 (36%) and discontinued in 5 subjects (19%), whereas oxaliplatin dose reduction was reported in eight cases (29%) and discontinued in eight subjects (29%).…”

Section: Resultsmentioning

confidence: 99%

Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review

Georgilis

Gavriatopoulou

Tsilimigras

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Interestingly, although it was a single-arm study, Satake et al reported the benefits of 3 monthsʼ CAPOX treatment as adjuvant therapy after resection of liver metastases, with lower neurotoxicity and higher 5-year survival rate of 87％ 14) . It may be acceptable to use adjuvant chemotherapy with fewer side effects in selected patients in the future.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Adjuvant Chemotherapy after Resection of Liver Metastases from Colorectal Cancer: Propensity Score Matching Analysis

Tahara,

Yamaguchi,

Horie

et al. 2023

JJCS

View full text Add to dashboard Cite

Background:We undertook this retrospective study to evaluate the efficacy of adjuvant chemotherapy after resection of liver metastases from colorectal cancer (colorectal liver metastases) using propensity score matching analysis.Methods: A total of 100 patients with colorectal liver metastases who had undergone hepatectomy between 2006 and 2019 were included in this study.The clinicopathological factors and long-term outcomes were compared between the patient group that had received adjuvant chemotherapy (Adj(+) group: n = 72) and the patient group that had not received adjuvant chemotherapy (non-adjuvant chemotherapy group; Adj(-) group: n = 28) following resection of the colorectal liver metastases. Propensity score matching was performed for clinicopathological factors, and 20 patients from each group selected.Results: Analyses prior to the matching revealed that the 3-year relapse-free survival rate was significantly higher in the Adj(+) group than in the Adj(-) group (43％ vs. 20％ ( p = 0.003)), while there was no significant difference in the 5-year cancer-specific survival rate between the two groups (67％ vs. 50 ％ ( p = 0.122)). Analysis after propensity score matching revealed that the 3-year relapse-free sur-

show abstract

“…However, about 80% of patients are affected by unresectable CRLM, due to bilobar multiple liver metastases and/or extrahepatic disease. Nowadays, systemic chemotherapy regimens [ 64 , 76 , 79 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 ] are proposed to convert patients with initially unresectable CRLM to obtaining and improving long-term surgical and oncological outcomes [ 23 , 82 , 90 , 91 , 92 , 93 ]. Nevertheless, some patients will progress during neoadjuvant chemotherapy with a debated role of liver resection in this subgroup.…”

Section: Survivalmentioning

confidence: 99%

Colorectal Cancer: Current Updates and Future Perspectives

Marcellinaro,

Spoletini,

Grieco

et al. 2023

JCM

View full text Add to dashboard Cite

Colorectal cancer is a frequent neoplasm in western countries, mainly due to dietary and behavioral factors. Its incidence is growing in developing countries for the westernization of foods and lifestyles. An increased incidence rate is observed in patients under 45 years of age. In recent years, the mortality for CRC is decreased, but this trend is slowing. The mortality rate is reducing in those countries where prevention and treatments have been implemented. The survival is increased to over 65%. This trend reflects earlier detection of CRC through routine clinical examinations and screening, more accurate staging through advances in imaging, improvements in surgical techniques, and advances in chemotherapy and radiation. The most important predictor of survival is the stage at diagnosis. The screening programs are able to reduce incidence and mortality rates of CRC. The aim of this paper is to provide a comprehensive overview of incidence, mortality, and survival rate for CRC.

show abstract

Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases

Cited by 4 publications

References 16 publications

Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review

Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review

Efficacy of Adjuvant Chemotherapy after Resection of Liver Metastases from Colorectal Cancer: Propensity Score Matching Analysis

Colorectal Cancer: Current Updates and Future Perspectives

Contact Info

Product

Resources

About